The Democratic Republic of Congo, currently at the heart of the global mpox outbreak, has taken a significant step toward combating the virus with the arrival of its first batch of vaccines on Thursday. This marks a major milestone in the fight against the disease, which has spread beyond Congo's borders to neighboring countries and even further, as the virus continues to pose a threat to public health. Despite the escalating spread of mpox, efforts to contain it have been hindered by the lack of vaccines across Africa, highlighting a disparity in global vaccine distribution.
The first shipment, consisting of 99,000 doses, was delivered to the capital, Kinshasa, after being manufactured by Bavarian Nordic and donated by the European Union. The plane carrying the doses touched down at Kinshasa's airport at 13:00 local time (12:00 GMT), where health officials, including Congo’s health minister, Samuel Roger Kamba Mulamba, were present. The health minister expressed confidence in the effectiveness of the vaccine, which has already shown promising results in the United States, and emphasized the urgency of distributing it to the provinces most affected by the outbreak, particularly Equateur and South Kivu. The government’s aim is to contain the virus as rapidly as possible and reduce further spread within the country.
In addition to the initial batch, a second shipment of vaccines is expected to arrive on Saturday, bringing the total to 200,000 doses. This is part of a larger effort by the European Union to provide a total of 566,000 doses to the regions most in need across Africa. Laurent Muschel, head of the EU Health Emergency Preparedness and Response Authority (HERA), confirmed that Burundi would likely be the next country to receive a shipment, though the distribution there is contingent on approval from its medical regulatory body.
The arrival of vaccines in Congo represents a significant moment in addressing the vast inequities that have characterized the global response to the mpox outbreak. During the 2022 outbreak, African countries had little to no access to the vaccines used to combat the disease in Europe and the United States, where they were widely available. This imbalance left many African nations particularly vulnerable, with limited tools to prevent the virus from spreading. The current vaccine delivery is expected to alleviate some of these disparities, providing much-needed protection to affected populations.
Congo’s government has announced that it will officially launch its nationwide vaccination campaign on October 8, allowing time for a comprehensive awareness campaign to be conducted. This campaign will aim to inform communities about the importance of the vaccine and address any lingering mistrust or hesitancy toward vaccination. In some areas, vaccine mistrust has been a challenge in the past, and authorities are keen to ensure that the new rollout is met with public understanding and cooperation.
Mpox, previously known as monkeypox, typically causes symptoms similar to the flu, along with painful, pus-filled skin lesions. While many cases are mild, the disease can be deadly, particularly in vulnerable populations. So far, Congo has reported 19,710 suspected cases of mpox in the first eight months of 2024, with 5,041 confirmed cases and 655 fatalities. The virus primarily spreads through close contact, including sexual contact, making containment efforts all the more urgent in affected regions.
The arrival of vaccines in Congo has offered a glimmer of hope in the fight against mpox, but significant challenges remain. The country’s ability to quickly and efficiently distribute the vaccines, particularly to remote areas where health infrastructure is limited, will be critical in determining the success of the campaign. Furthermore, ensuring public buy-in for the vaccination program will be essential to reaching the populations most at risk of contracting the disease.
As Congo rolls out its vaccination program, health authorities are hopeful that this could mark a turning point in the battle against mpox, not just in the country but across Africa, where the virus has posed an ongoing threat to public health. With the support of the international community, Congo’s efforts may help to stem the tide of infection and prevent further loss of life.
Â
